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Abstract: Lipedema is an adipose tissue disorder characterized by the disproportionate increase of
subcutaneous fat tissue in the lower and/or upper extremities. The underlying pathomechanism
remains unclear and no molecular biomarkers to distinguish the disease exist, leading to a large
number of undiagnosed and misdiagnosed patients. To unravel the distinct molecular characteristic
of lipedema we performed lipidomic analysis of the adipose tissue and serum of lipedema versus
anatomically- and body mass index (BMI)-matched control patients. Both tissue groups showed no
significant changes regarding lipid composition. As hyperplastic adipose tissue represents low-grade
inflammation, the potential systemic effects on circulating cytokines were evaluated in lipedema and
control patients using the Multiplex immunoassay system. Interestingly, increased systemic levels of
interleukin 11 (p = 0.03), interleukin 28A (p = 0.04) and interleukin 29 (p = 0.04) were observed. As
cytokines can influence metabolic activity, the metabolic phenotype of the stromal vascular fraction
was examined, revealing significantly increased mitochondrial respiration in lipedema. In conclusion,
despite sharing a comparable lipid profile with healthy adipose tissue, lipedema is characterized by
a distinct systemic cytokine profile and metabolic activity of the stromal vascular fraction.
Keywords: lipedema; adipose tissue; lipidomics; mitochondrial respiration
1. Introduction
Lipedema is an adipose tissue disorder characterized by the disproportionate increase
of subcutaneous fat tissue. The disease almost exclusively affects women in family clusters
and onset is frequently associated with phases of hormonal changes, such as puberty,
pregnancy and menopause. The disproportional fibroadipose tissue accumulation around
legs and sometimes arms can lead to considerable disability, daily functioning impairment
and psychosocial distress [1]. Due to the lack of epidemiological studies the exact preva-
lence is unknown. Nonetheless, rates are estimated at a considerable 7–15% [2,3]. Neither
histopathological nor molecular hallmarks exist; thus, a large number of patients remain
undiagnosed or misdiagnosed as other clinical entities, such as obesity and lymphedema.
The accumulation of adipose tissue characterizing lipedema is a result of the prolifera-
tion of adipose stem cells and hypertrophy of adipocytes, leading to a distinct lipedema
phenotype [4]. Recent research suggests that lipedema adipose derived stems cells (ASCs)
have a higher adipogenic differentiation potential compared to control ASCs which might
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contribute to the disease pathogenesis [5]. Previous work has demonstrated slight differ-
ences in the systemic lipid metabolism in lipedema with systemic lipid values ranging
between the upper physiological range and slight pathological range [6]. The biological
interpretation of these findings necessitates further research to unravel potential differences
and thus potential biomarkers in the lipid composition between lipedema and control
patients, both locally and systemically.
Recent studies conducted by multiple research groups, including ours, have revealed
a distinct immune cell composition in lipedema characterized by increased macrophage
infiltration whereas the T-cell compartment remains unchanged [7,8]. Interestingly, an M2
macrophage polarization phenotype was identified, attributed to CD163 overexpression [8].
The presence of such an immune signature is commonly associated with changes in cytokine
levels. Initial investigations showed increased systemic levels of vascular endothelial
growth factor (VEGF)-C which might be related to the increased macrophage infiltrate.
In addition, downregulation of lymphatic-related cytokines such as Tie2, VEGF-A and
VEGF-D which could be linked to a modified vascular permeability, developed secondarily
to lipedema progression [8].
As the underlying pathophysiological mechanisms remain unclear, the identification
of biomarkers would facilitate the timely diagnosis and treatment of the affected patients at
an early stage. Therefore, this work investigates the fat tissue and serum in women suffering
of lipedema, focusing on the alterations in local and systemic lipid composition, systemic
cytokine profile changes and the stromal vascular fraction’s metabolic phenotype to gain
inside into the pathophysiology of lipedema and potentially identify reliable biomarkers.
2. Results
2.1. Adipocyte Hypertrophy Characterizes Lipedema
Previous work of our laboratory and others has revealed increased adipocyte size
in lipedema (L) versus control (C) samples in anatomically matched tissue biopsies. To
verify this finding, we analyzed the adipocyte size measuring the adipocyte cell area (in
µm2) in hematoxylin/eosin stained sections of adipose tissue samples in a larger group
of lipedema patients (C n = 10, L n = 20) using control patients with comparable BMI.
We confirmed that lipedema patients exhibited significant adipose tissue hypertrophy
compared to anatomically and BMI matched (C: 27.9 ± 4.2 kg/m2, L: 27.55 ± 2.5 kg/m2)
patients as seen in Figure 1A–C (C: 8874 ± 2386 µm2 vs. L: 12,349 ± 2113 µm2). We used
perilipin staining to verify that the structures quantified were indeed adipose cells and not
lipid droplets (Figure 1A).
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Figure 1. Adipocyte hypertrophy in lipedema. (A) Hematoxylin/eosin (H/E) and Perilipin immunostaining of paraffin-
embedded adipose tissue demonstrating that even the largest adipocytes remain perilipin positive. The arrows indicate the
large perilipin-positive adipocytes. Scale bar: 100 µm. (B) Quantification of the adipocyte size using the hematoxylin/eosin
sections reveals adipose tissue hypertrophy. (C) The body mass index (BMI) values of the control and lipedema patients
appear comparable. N (Control): 10 patients and N (Lipedema): 20 patients. The p-values indicate the statistical significance
in comparison to the control (two-tailed Student t-test).
2.2. Lipid Mass Spectrometry Analysis Reveals a Comparable Lipid Composition in the Tissue and
Serum of Lipedema Versus Control Patients
As adipocyte tissue hypertrophy appears to be a characteristic of lipedema we then
evaluated whether this might reflect into the lipid composition in lipedema tissue or serum.
The oily phase of the lipoaspirate as well as serum of patients (after 8 h of starvation) was
analyzed by mass spectrometry.
The lipoaspirate and serum of 10 control and 10 lipedema patients was included in the
study. Finally, lipoaspirate from 7 control and 9 lipedema patients and serum of 8 control
and 8 lipedema patients were included into the analysis, excluding samples that showed
visual contamination with blood (leading to lipid oxidation) [9]. The analysis of the oily
phase of the aspirate and the serum revealed no statistically significant alterations in the lipid
composition between the disease and the control groups (Figure 2A,B and Figure 3A,B).
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Figure 2. Lipid mass spectrometry analysis reveals a comparable lipid composition in the tissue of
lipedema versus control patients (A) Lipidomic heat map showing log2 fold change of molecular
lipid species comparing tissue of lipedema versus control patients using unsupervised hierarchical
clustering. Each horizontal row represents a molecular lipid and each vertical column represents a
tissue sample. Relative change of each lipid is indicated by coloring, and the scale is represented in
the color key. (B) Volcano plot showing no statistically significant alterations in the lipid composition
between the disease and the control groups. N (Control): 7 patients and N (Lipedema): 9 patients.
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Figure 3. Lipid mass spectrometry analysis reveals a comparable lipid composition in the serum of
lipedema versus control patients (A) Lipidomic heat map showing log2 fold change of molecular
lipid species comparing serum of lipedema versus control patients using unsupervised hierarchical
clustering. Each horizontal row represents a molecular lipid and each vertical column represents a
serum sample. Relative change of each lipid is indicated by coloring, and the scale is represented in
the color key. (B) Volcano plot showing no statistically significant alterations in the lipid composition
between the disease and the control groups. N (Control): 8 patients and N (Lipedema): 8 patients.
2.3. A Distinct Cytokine Profile Characterizes Lipedema
To dissect the differences of lipedema as compared to BMI-matched controls a broad
analysis of the serum cytokine profile of lipedema versus control patients was performed
using Multiplex. Thirty-seven cytokines were evaluated and 22 of them were detectable in
the isolated serum (Figure 4A). The cytokines not detected in the serum included the fol-
lowing: interferons beta and gamma, (IFN-β, IFN-γ) interleukins 2, 8, 10, 12(p40), 12(p70),
19, 26, 27(p28), 32, 35 (IL-2, IL-8, IL-10, IL-12(p40), IL-12(p70), IL-19, IL-26, IL-27(p28),
IL-32, IL-35), tumor necrosis factor superfamily 14 (TNFSF14) and the matrix metallopro-
teinases 1 and 3 (MMP-1, MMP-3). Out of the ones detected, IL-11 (C: 2.07 ± 0.51 vs.
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L: 2.64 ± 0.65 pg/mL; 95%CI: C: 1.65–2.68 vs. L: 2.31–2.96 pg/mL), IL-28A (C: 39.98 ± 5.61
vs. L: 46.17 ± 6.65 pg/mL; 95%CI: C: 35.41–44.57 vs. L: 42.98–49.37 pg/mL) and IL-29
(C: 74.13 ± 20.58 vs. L: 96.19 ± 29.1 pg/mL; 95%CI: C: 58.62–89.66 vs. L: 82.22–110.2 pg/mL)
were significantly increased in the serum of lipedema patients (Figure 4B–D).
 – –
  – –







Figure 4. Inflammatory cytokine and chemokine profile of lipedema and control patients. (A) Multiplex immunoassay
using serum samples from lipedema and control patients. Heat map showing log 2-fold changes in concentration of 22
cytokines/chemokines normalized by mean value of control samples. (B–D) Concentration of IL1 (B), IL28A (C), and IL29
(D) were significantly increased in the serum of lipedema patients. N (Control): 10 patients and N (Lipedema): 20 patients.
The p-values indicate the statistical significance in comparison to the control (two-tailed Student t-test).
As liposuction is currently the only treatment option for lipedema we then sought to
investigate any potential systemic effects in the circulating cytokines upon surgical treatment.
An analysis of the limb volume pre- and one year post-operatively was conducted first to
demonstrate that any possible observed changes are not due to significant volume deviations
at the two evaluated timepoints. Indeed, no significant volumetric changes were detected
in the affected extremities pre-and post-operatively as depicted in Figure 5A,B. The serum
of seven patients was examined directly pre-operatively and one year post-operatively
using Multiplex. Out of the twenty-two detected cytokines, interferon alpha (IFNα) (Pre-
OP: 49.29 ± 10.06 vs. Post-OP: 42.15 ± 12.17 pg/mL; 95%CI: Pre-OP: 39.24–59.35 vs.
Post-OP: 29.99–54.32 pg/mL) and interleukin 34 (Pre-OP: 237.21 ± 188.97 vs. Post-OP:
115.6 ± 56.78 pg/mL; 95%CI: Pre-OP: 48.44–426 vs. Post-OP: 58.88–172.3 pg/mL) were
found to be decreased one year post-operatively.
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Figure 5. Inflammatory cytokine and chemokine profile in the serum of lipedema patients pre- and one year post-
operatively (A,B) Analysis of the limb volume pre- and one year post-operatively observed no significant volumetric
changes. N: 5 patients (C,D) Serum was examined pre-operatively and one year post-operatively using Multiplex. Out
of 22 cytokines detected, interferon alpha (IFNα) and interleukin 34 (IL34) blood concentrations were decreased one year
post-operatively. N: 7 patients. The p-values indicate the statistical significance in comparison to the control (two-tailed
paired Student t-test).
2.4. Increased Oxidative Metabolism Capacity of the SVF from Lipedema Patients
After discovering a distinct cytokine profile in lipedema and knowing that inflamma-
tory cytokines potentially influence metabolic activity of tissues, we set out to determine
the metabolic status of the stromal vascular fraction (SVF) in lipedema and control patients.
To evaluate the mitochondrial function/activity of the SVF we performed a mitochondrial
stress test using an Agilent Seahorse XFe96 Analyzer. At the basal respiration (prior to ad-
dition of mitochondrial inhibitors/uncouplers) the ATP linked respiration (calculated after
oligomycin administration) and the non-mitochondrial respiration (after antimycin A and
rotenone administration) no significant alterations were observed. With the administration
of the uncoupler carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) the maxi-
mal possible oxygen consumption was determined. The SVF of lipedema patients showed
a highly increased and significant maximal respiration (OCR: C: 9.43 ± 2.95 pmol/min;
L: 40.6 ± 8.48 pmol/min; 4-fold increase; and p = 0.0005) compared to controls, further
suggesting that lipedema is associated with an enhanced mitochondrial function of the
SVF (Figure 6).
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Figure 6. Oxygen consumption rates of stromal vascular fraction (0.15 × 106 cells/well) of lipedema and controls patients.
(A) At the basal respiration, the ATP (adenosine triphosphate) linked respiration, the non-mitochondrial respiration, no
significant alterations were observed. Each data point represents mean value of 4 or 5 patients. (B) Maximal respiration
revealed a 4-fold increase in lipedema patient compared to controls. Maximal respiratory capacity is derived by subtracting
the ORC (oxygen consumption rate) value at time point 6 from the value at time point 7. Each data point represents mean
value of one patient. N (Control): 4 patients and N (Lipedema): 5 patients. The p-values indicate the statistical significance
in comparison to the control (two-tailed Student t-test).
3. Discussion
In the present study we examined the lipid composition in adipose tissue and serum
of lipedema patients as well as the serum inflammatory cytokine profile and adipose tissue
metabolic profile compared to gender-, anatomically- and BMI-matched control samples
undergoing elective plastic surgery procedures.
A hallmark of lipedema is the profound morphologic remodeling of adipose tissue,
exhibiting a prominent adipocyte hypertrophy. The present study confirms these results
which were first demonstrated in previously published histological studies [6,7]. Changes,
such as increased adipocyte size, often reflect metabolic states within those cells [10].
Our previous research confirmed an aberrant lipid metabolism and a distinct adipogenic
gene expression profile. Furthermore, serum triglycerides, LDL and cholesterol levels
were found to be slightly but also significantly increased with values ranging from the
upper physiological to pathologic levels [6]. However, little is known about the lipids that
comprise lipedema adipose tissue or circulate systemically in the serum. Therefore, we per-
formed a lipidomic analysis of lipoaspirates and serum from lipedema and control patients
and identified 400 lipids present in a similar abundance in both groups. Accordingly, our
data suggest that lipedema is not a condition of fundamentally altered or grossly defective
lipid metabolism. The slight changes in the serum lipids from previous studies could not
be confirmed, possibly due to our study being underpowered.
These results clearly allow a differentiation of lipedema from lymphedema and obe-
sity. In the lipidomic profile of plasma from obese patients a significant reduction in
lyso-phosphatidylcholine levels is visible [11] which does not occur in lipedema. The
analysis of lipid molecules in the oil of lipoaspirates from primary lymphedema patients
exhibits a signature of increased cyclopropane-type fatty acids and inflammatory mediators’
arachidonic acid and ceramides. Interestingly C20:5 and C22:6 omega-3-type lipids were
increased in the adipose tissue correlating with the duration of lymphedema. Neverthe-
less, lymphedema has a normal lipid profile containing a signature of inflammation and
omega-3-lipids [12].
As a second hallmark, lipedema is associated with a state of low-grade inflammation.
Our previous research showed that a distinct immune cell infiltration occurs in lipedema,
characterized by the infiltration of M2 polarized macrophages [8]. The presence of such an
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immune signature is associated with systemic changes reflected in circulating cytokines’
levels. Only limited data of the cytokine profile in lipedema is available. To elucidate
potential differences, we performed a Multiplex Immunoassay System to evaluate 37 circu-
lating cytokines in the serum of lipedema versus BMI-matched control patients as well as
lipedema patients pre- and one year post-operatively.
The comparison between lipedema and control patients (pre-operatively) revealed
significantly increased IL-11, interferon type III family IL 29 (interferon lambda 1) and
IL28A (interferon lambda 2) levels. IL-28A and IL-29 are secreted primarily by dendritic
cells and macrophages [13] and induce antiviral responses and primarily act at anatomical
barriers, including epithelial surfaces [14]. The third upregulated cytokine, IL-11, regulates
adipogenesis by binding IL-11Rα receptor [15,16]. The primary source for IL-11 is the
stromal vascular fraction [17] which is increased in adipose tissue of lipedema patients [4].
The alterations in circulating IL11, IL28A and IL29 levels are possibly linked to the specific
immunological niche present in lipedema.
It was of particular interest to evaluate the potential systemic effect of liposuction,
the currently most widely accepted treatment for lipedema, in regard to the changes in
circulating cytokines. Serum was isolated from blood samples taken after eight hours
of starvation either directly before surgery or one year after surgery. INFα2 and IL34
were found to be significantly reduced in the patients after surgery. IL-34 is expressed in
human adipose tissues by adipocytes, SVF and its circulating concentration is significantly
elevated in obese patients. IL-34 is associated with obesity-induced inflammation and
the pathogenesis of related diseases such as insulin resistance [18]. On the other hand,
IFN-α inhibits adipocyte differentiation and lipid droplet accumulation [19] and can induce
apoptosis in adipose tissue cells [20]. Macrophage-derived IFN-α, together with IL-12
and IL-18, efficiently induces IFN-γ expression [21]. Liposuction has been found to have
persistent and long-term beneficial effects without relapse over up to 12 years [22]. It
is not clear whether the altered cytokine milieu post-surgery could contribute to this
beneficial effect or if it is the result of the reduced adipose tissue with its remarkable
secretory capacity. In contrast to cosmetic liposuction the main goal of surgical treatment
of lipedema is not the volume reduction but rather the reduction of the painful fat tissue
accumulation linked with sensitivity to pressure, feeling of tension, bruising and general
impairment to quality of life. Thus, the marginal volumetric changes in this patient group
(with the moderate BMI values) following liposuction are not surprising. The underlying
mechanisms by which liposuction may downregulate INFα2 and IL34 serum levels is a
subject of further investigation.
It is known that circulating cytokines influence many cellular metabolic activities. The
metabolic activity of the adipose tissue is particularly determined by the interplay between
adipocytes, preadipocytes, endothelial cells and immune cells which are all present in the
SVF and appear altered in lipedema tissue in terms of cell content and cellular subtype
composition [4]. To evaluate the metabolic activity of the adipose milieu, we analyzed SVF
cells isolated from liposuction material of lipedema and control patients. The isolated cells
from lipedema showed a higher oxygen consumption rate than control SVF under maximal
respiratory stress (uncoupling), indicating that lipedema SVF has an increased oxidative
metabolic capacity. These results point toward an increased activation state. An essential
part of SVF consists of macrophages which have a potential role in lipedema. An altered
macrophage metabolism not only is a characteristic of polarized macrophage subsets, it
is also a prerequisite for proper polarization and inflammatory regulation. Notably, the
inhibition of glycolysis or OXPHOS/FAO has been demonstrated to impair M1 or M2
activation [23,24]. Indeed, metabolic changes affect metabolite concentrations that are
direct regulators of the macrophage phenotype [25,26].
The current study has been limited by the relatively low number of patients enrolled.
The various test material was limited and sufficient amounts from every patient were not
available to perform all experiments, resulting in differential number of patients (from
the same cohort) being used for the various tests. These limitations were overcome by
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the very consistent and comparable characteristics of the selected and analyzed groups
(anatomic location, age and BMI). Particularly, the sample size of the patients who were
examined pre-and post-operatively was low and the alteration in the cytokine profile was
slightly variable. These results ranged from massive downregulation to no changes in
the post-surgery cytokine profile (Figure 5C,D) which could be attributed to individual
differences. Nevertheless, a moderate but significant effect could be observed and these
preliminary results need to be proven in a larger sample size.
Our results further increase the understanding of lipedema and underpin the distinct
nature of the disease. Notwithstanding the characteristic adipose tissue hypertrophy, the
lipid composition in lipedema is comparable to the controls. Serum lipid markers do not
appear to be sufficient to define or diagnose the disease, suggesting that potential biomarker
development should be based elsewhere. Interestingly, a distinct systemic cytokine profile
is present in lipedema and our preliminary results offer an opportunity to understand better
how the symptom relief after surgery mirrors certain systemic changes potentially linked to
immunological components. So far there are no blood-based markers to diagnose lipedema.
The alterations in the cytokine milieu, which need to be confirmed in larger patient cohorts,
offer a promising opportunity for the development of lipedema biomarkers. The alterations
in the SVF metabolism present an intriguing finding, suggesting a metabolically active
adipose tissue. This requires further elucidation in regard to the mechanisms involved
and particularly the role of the immune component in the regulation of the adipose tissue
metabolism in lipedema.
4. Materials and Methods
4.1. Patients
The protocols of the current study were approved prior to patient recruitment by the
Ethical Committee of the University Hospital Goettingen, State of Lower Saxony, Germany
(Nr. 23-11-17, accepted on 23. November 2017) and the study has been conducted according
to the principles of the Declaration of Helsinki and its amendments. All patients were
informed in detail prior to the surgical procedures in oral and written form and provided
their written informed consent. The samples were obtained from lipedema and BMI- as
well as age-matched control female patients. Lipedema was diagnosed based on the criteria
of Wold et al. [27], namely (1) female, (2) bilateral increase of the adipose tissue of the
lower extremities sparing the feet, (3) negative Stemmer’s sign, (4) pain, tenderness and
a tendency to bruise in the affected extremities, (5) adiposity demonstrated resistance
to attempts at weight loss or persistence to extremity elevation. All lipedema patients
included met the aforementioned criteria. The tissue derived from the proximal part of the
thigh, as anatomically matched biopsies. The patient characteristics of the study cohort
are provided in the Table 1. The number of patients evaluated in each type of analysis is
provided in the Appendix A Table A1.
Table 1. Patient characteristics.
Patient Characteristics Study Cohort






Mean age (in years)
Lipedema patients 48.65 ±.11
Control patients 49.8 ± 8.6
Mean BMI (in kg/m2)
Lipedema patients 27.55 ± 2.45
Control patients 27.85 ± 4.2
Int. J. Mol. Sci. 2021, 22, 3313 11 of 14
Table 1. Cont.






4.2. Tissue Collection and Immunohistochemistry
During the operating procedure fat tissue specimens for histology were collected and
fixed for 4 h in paraformaldehyde/phosphate-buffered saline (PBS) at 4 ◦C. Subsequently,
the samples were embedded in paraffin.
For (immuno-)histological analysis and assessment of adipose tissue architecture the
specimens were cut into 5-µm thick paraffin sections and stained at the Department of
Pathology of the University Medical Center Goettingen according to standardized protocols.
For the perilipin stain, paraffin-embedded sections were deparaffinized and rehydrated.
Antigen retrieval was performed with proteinase K (Dako S3020), and endogenous per-
oxidase activity was blocked using Bloxall (Vector Laboratories, Burlingame, CA, USA;
Vector SP-6000). After blocking (Vectastain Mouse-HRP-Kit; Vector PK-6102 plus 1.5%
horse serum), the sections were incubated with guinea pig antihuman perilipin antibody
(Fitzgerald Industries International, Acton, MA, USA; 20R-PP004, 1:200) at 4 ◦C overnight.
After washing steps with PBS, bound antibody was visualized using the Vectastain Kit
with DAB substrate, according to the manufacturer’s instructions.
Histology images were obtained using a Leica Leitz DM RXE microscope equipped
with a Leica DFC490 camera, and up to five images per tissue were acquired using a PL
Fluotar 20x/0.5 numerical aperture or PL Fluotar 40x/0.7 numerical aperture objective.
Morphometric analysis of adipocyte characteristics was performed using ImageJ software
(National Institutes of Health, Bethesda, MD, USA).
4.3. Serum Isolation
For the cytokine evaluation 10 mL of blood was collected in a S-Monovette (Sarstedt,
Nuernbrecht, Germany) preoperatively and upon 8–10 (6–8 h) h of starvation and one year
postoperatively. Blood was left to coagulate for 30 min at RT and then was centrifuged for
10 min at 1000× g. Serum was aliquoted and stored at −80 ◦C until usage.
4.4. Lipid Extraction
A total of 200 µL of the lipid containing sample was dispersed in 1.5 mL of methanol
containing 50 µg/mL butyrated hydroxytoluene (BHT) in a glass tube with a PTFE (poly-
tetrafluoroethylene) lid, both baked at 180 ◦C for 24 h prior to usage. A total of 5 mL of
methyl tert-butyl ether (MTBE) was added and the tube was agitated at room temperature
for one hour. Then, 1.25 mL of water was added and the tube was briefly mixed and then
centrifuged for 10 min at 1000× g. The upper phase containing most of the lipids was
then transferred to a new glass tube and stored at −80 ◦C for a max of 30 days [28]. All
chemicals were obtained from Sigma (Sigma-Aldrich, St. Louis, MO, USA) at the highest
available purity.
4.5. Mass Spectrometry
The solvent was removed under a stream of liquid nitrogen and the lipids were solu-
bilized in 0.5 mL of methanol (MeOH). After shaking them for 20 min at room temperature,
samples were diluted 5 times to a final concentration of 50% MeOH and directly injected
into the liquid chromatography-mass spectrometry (UPLC-MS) system for further analysis.
Lipids were separated on a nanoAquity UPLC (Waters) equipped with a HSS T3 capillary
column (150 µm × 40 mm, 1.8 µm particle size, Waters). Buffer A was 5 mM ammonium
acetate in 5% acetonitrile; buffer B was 5 mM ammonium acetate in 90% isopropanol and
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10% acetonitrile. A 10-min gradient from 2% B to 98% B was applied at an initial flow rate
of 3 µL/min, linearly decreased to 2.5 µL/min. The injection volume was 1 µL. The UPLC
was coupled to a Q-Exactive MS (Thermo) by a nanoESI source. MS data was acquired
using positive polarity and data-dependent acquisition (dd-MS2) in top-5 scan mode,
over a mass range of 80 to 1200 m/z at a resolution of 70,000 for MS and 17,500 for MS2.
Normalized collision energy was stepped from 20 to 30. All solvents used were of quality
HPLC grade (Chromasolv, Sigma-Aldrich, St. Louis, MO, USA). Data was analyzed using
Progenesis QI software (Waters Corportation, Milford, MA, USA) using the LipidMaps
database (www.lipidmaps.org) and R statistical software (www.r-project.org). Complete
lipidomic analysis is shown in the Supplementary Table S1.
4.6. Isolation of the Stromal Vascular Fraction
Adipose tissue was digested with 2 mg/mL collagenase dissolved in RPMI glutamax
medium and was incubated at 37 ◦C under moderate shaking for 1 h. After centrifugation
at 1000× g for 5 min, the cell pellet was incubated with erythrocyte lysis buffer for 10
min on ice to eliminate red blood cells. The cell suspension was diluted in PBS and the
supernatant was aspirated after centrifugation for 5 min at 1000× g. The pellet was washed
with PBS and filtered through a 70 µm cell strainer. After another centrifugation step at
500× g for 5 min, the supernatant was removed, and the isolated SVF cells were frozen in
5% FBS and 5% DMSO.
4.7. Multiplex Analysis
Cytokine quantification in the human serum samples was performed using Bio-Plex
Pro Human Inflammation Panel 1, 37-Plex (Bio-Rad Laboratories, Hercules, CA, USA)
according to the manufacturer’s instructions.
4.8. Measurement of SVF Mitochondrial Respiration
For the Mito Stress Test, SVF isolated from control and lipedema patient adipose
tissue was plated at 0.15 × 106 cells/well as four technical replicates (for each patient)
in complete IMDM (L-glut, 10% FBS and penstrep) and left to adhere overnight on a
Seahorse Assay Plate at 37 ◦C in a humified 5% CO2 incubator. IMDM was replaced with
Seahorse Assay Medium pH 7.4 supplemented with 10 mM glucose, 2 mM L-glutamine
and 1 mM sodium pyruvate and incubated for one hour at 37 ◦C in a non-CO2 incubator.
Thereafter, the cells were transferred to the Seahorse XFe96 Extracellular Flux Analyzer
(Agilent Technologies, Santa Clara, CA, USA) where the cells were treated sequentially
with 1 µM oligomycin, 1 µM FCCP and 0.5 µM Rotenone/antimycin A and analyzed
for mitochondrial respiration. Each technical replicate was normalized to the amount
of DNA/well which was determined using the CyQuant kit (C35011, Thermo Fisher,
Zug, Switzerland), according to the manufacturer’s instructions. A mean was calculated
per patient from the technical replicates and then these values were used for the further
statistical analysis. For the calculation of the maximal respiration, the ORC value at time
point 6 was subtracted from the value at time point 7 and plotted separately.
4.9. Statistical Analysis
All data are expressed as mean ± SD; boxplot show the average and the 25–75 per-
centiles while the whisker plots exhibit the 5–95 percentiles. Outliers have been identified
with the Grubb’s test and have been excluded from the analysis. A non-parametric un-
paired Mann–Whitney U-test was performed for non-Gaussian distribution, whereas a
two-tailed Student t-test was performed for Gaussian-distribution. The results of the
statistical analysis in lipid spectrometry were corrected for multiple testing using the
Benjamini-Hochberg method.
Sample sizes and statistical analyses are indicated in the figure legends, unless other-
wise mentioned. Statistical analyses were performed using GraphPad Prism V8.0 (Graph-
Pad Software, San Diego, CA, USA). p < 0.05 was accepted as statistically significant.
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Table S1 shows the complete lipidomic analysis of the adipose tissue and serum of
lipedema and control patients.
Supplementary Materials: The following are available online at https://www.mdpi.com/1422-006
7/22/7/3313/s1.
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Appendix A
Table A1. Number of patients used in each type of analysis.








30 30 20 10
Lipedema patients 20 20 10 * 5













Female 30 30 20 10
Male 0 0 0 0
* Samples with visible amount of blood contamination were excluded. ** one control patient was excluded from the analysis as an outlier.
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